Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3298
Glycomics / Glycobiology Market is poised to register a CAGR of 14.7% during the forecast period 2022 to 2028. The rising research and development activities pertaining to glycomics, increased investments by biotech and pharma companies and rising demand for proteomics are some of the key factors driving the glycomics/glycobiology market growth. Furthermore, the glycoscience sector is growing rapidly and glycans are crucial in biological research and processes in understanding biology in a comprehensive manner. As per the Biotech Briefing in 2018, the average expenditure for research and development of biotechnology companies has risen by over 15% from 2016 to 2017. Furthermore, the government bodies are increasingly involved in undertaking the initiatives for conducting extensive research activities related to glycomics. For instance, the Australian government has invested over USD 10 billion for research innovations and activities during the period 2017-2018. Furthermore, the Irish government declared an expenditure of over USD 5 billion in 2015 for increasing research activities across the country. Such initiatives shall boost the growth of the market. Market Segmentation: By Product • Enzymes o Glycosidases o Neuraminidases o Glycosyltransferases o Sialyltransferases o Others • Kits o Glycan Labeling Kits o Glycan Purification Kits o Glycan Release Kits o Others • Reagents o Glycoproteins o Monosaccharides o Oligosaccharides o Others • Instruments o Mass Spectrometers o HPLC o MALDI-TOF o Array Systems o Others By Application • Drug Discovery & Development • Disease Diagnostics • Other Applications By End User • Academic Research Institutes • Pharmaceutical and Biotechnology Companies • Clinical Laboratories By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is bifurcated into product, application, end user and region. The product segment is categorized into enzymes, instruments, kits, carbohydrates and reagents & chemicals. The enzymes segment is predicted to hold the largest glycomics/glycobiology market share owing to the wide range of applications in diagnostics and research and increased sale of these products. The application segment is categorized into drug discovery and development, disease diagnostics and other applications. The drug discovery and development segment is predicted to lead the market and this can be credited to an increased insistence for personalized medicines and emphasis on advanced drug development. The end user segment is fragmented into academic research institutes, pharmaceutical and biotechnology companies and clinical laboratories. The pharmaceutical and biotechnology company segment is anticipated to dominate the market owing to the rise in the number of investments made by these companies for research and development of glycomics. Regional Analysis: The North America region is expected to subjugate the market, and this can be primarily credited to increased investments in research activities pertaining to glycomics and a strong presence of key market players in the region. The Asia Pacific region, on the other hand, is predicted to grow at a substantial rate during the forecasted timeframe owing to the increased healthcare expenditure and operational expanse of biotech and pharma companies in the region. Competitive Landscape: The key market players included are Merck KGaA, Agilent Technologies, Thermo Fisher Scientific, New England Biolabs, Shimadzu Corporation, Takara Bio, S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation, Asparia Glycomics S.L., Bio-Techne, Bruker Corporation, Danaher Corporation, RayBiotech, Z Biotech, Chemily Glycoscience, Dextra Laboratories, Lectenz Bio, Ludger Ltd. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global glycomics/glycobiology market by product, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The rising research and development activities pertaining to glycomics, increased investments by biotech and pharma companies and rising demand for proteomics are some of the key factors driving the glycomics/glycobiology market growth. Furthermore, the glycoscience sector is growing rapidly and glycans are crucial in biological research and processes in understanding biology in a comprehensive manner. As per the Biotech Briefing in 2018, the average expenditure for research and development of biotechnology companies has risen by over 15% from 2016 to 2017. Furthermore, the government bodies are increasingly involved in undertaking the initiatives for conducting extensive research activities related to glycomics. For instance, the Australian government has invested over USD 10 billion for research innovations and activities during the period 2017-2018. Furthermore, the Irish government declared an expenditure of over USD 5 billion in 2015 for increasing research activities across the country. Such initiatives shall boost the growth of the market.
Market Segmentation:
By Product • Enzymes o Glycosidases o Neuraminidases o Glycosyltransferases o Sialyltransferases o Others • Kits o Glycan Labeling Kits o Glycan Purification Kits o Glycan Release Kits o Others • Reagents o Glycoproteins o Monosaccharides o Oligosaccharides o Others • Instruments o Mass Spectrometers o HPLC o MALDI-TOF o Array Systems o Others By Application • Drug Discovery & Development • Disease Diagnostics • Other Applications By End User • Academic Research Institutes • Pharmaceutical and Biotechnology Companies • Clinical Laboratories By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is bifurcated into product, application, end user and region. The product segment is categorized into enzymes, instruments, kits, carbohydrates and reagents & chemicals. The enzymes segment is predicted to hold the largest glycomics/glycobiology market share owing to the wide range of applications in diagnostics and research and increased sale of these products. The application segment is categorized into drug discovery and development, disease diagnostics and other applications. The drug discovery and development segment is predicted to lead the market and this can be credited to an increased insistence for personalized medicines and emphasis on advanced drug development. The end user segment is fragmented into academic research institutes, pharmaceutical and biotechnology companies and clinical laboratories. The pharmaceutical and biotechnology company segment is anticipated to dominate the market owing to the rise in the number of investments made by these companies for research and development of glycomics.
Regional Analysis:
The North America region is expected to subjugate the market, and this can be primarily credited to increased investments in research activities pertaining to glycomics and a strong presence of key market players in the region. The Asia Pacific region, on the other hand, is predicted to grow at a substantial rate during the forecasted timeframe owing to the increased healthcare expenditure and operational expanse of biotech and pharma companies in the region.
Competitive Landscape:
The key market players included are Merck KGaA, Agilent Technologies, Thermo Fisher Scientific, New England Biolabs, Shimadzu Corporation, Takara Bio, S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation, Asparia Glycomics S.L., Bio-Techne, Bruker Corporation, Danaher Corporation, RayBiotech, Z Biotech, Chemily Glycoscience, Dextra Laboratories, Lectenz Bio, Ludger Ltd.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global glycomics/glycobiology market by product, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Esoteric Testing Market Variables, Trends & Scope 4.1. Market LineProducts Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Esoteric Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Esoteric Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Esoteric Testing Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Infectious Diseases Testing 7.2. Endocrinology Testing 7.3. Oncology Testing 7.4. Genetic Testing 7.5. Toxicology Testing 7.6. Immunology Testing 7.7. Neurology Testing 7.8. Others 8. Esoteric Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Chemiluminescence Immunoassay 8.2. Enzyme-Linked Immunosorbent Assay 8.3. Mass Spectrometry 8.4. Real-Time Pcr 8.5. Flow Cytometry 8.6. Radioimmunoassay 8.7. Other Technologies 9. Esoteric Testing Market, By Laboratory Type Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Independent & Reference Laboratories 9.2. Hospital Laboratories 10. North America Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. LabCorp 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Quest Diagnostics 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. OPKO Health 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Miraca Holdings 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Myriad Genetics 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Sonic Healthcare 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Primary Health Care 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Healthscope 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Foundation Medicine 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Acm Global Laboratories 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.ARUP Laboratories 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Fulgent Genetics 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.Invitae 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14.Mayo Medical Laboratories 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 16.15.Spectra Laboratories 16.15.1. Company Overview 16.15.2. Product Portfolio 16.15.3. SWOT Analysis 16.15.4. Financial Overview 16.15.5. Strategic Overview 16.16.American Medical Laboratories 16.16.1. Company Overview 16.16.2. Product Portfolio 16.16.3. SWOT Analysis 16.16.4. Financial Overview 16.16.5. Strategic Overview 16.17.Genomic Health 16.17.1. Company Overview 16.17.2. Product Portfolio 16.17.3. SWOT Analysis 16.17.4. Financial Overview 16.17.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Esoteric Testing Market Variables, Trends & Scope 4.1. Market LineProducts Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Esoteric Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Esoteric Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Esoteric Testing Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Infectious Diseases Testing 7.2. Endocrinology Testing 7.3. Oncology Testing 7.4. Genetic Testing 7.5. Toxicology Testing 7.6. Immunology Testing 7.7. Neurology Testing 7.8. Others
8. Esoteric Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Chemiluminescence Immunoassay 8.2. Enzyme-Linked Immunosorbent Assay 8.3. Mass Spectrometry 8.4. Real-Time Pcr 8.5. Flow Cytometry 8.6. Radioimmunoassay 8.7. Other Technologies
9. Esoteric Testing Market, By Laboratory Type Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Independent & Reference Laboratories 9.2. Hospital Laboratories
10. North America Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Esoteric Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. LabCorp 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Quest Diagnostics 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. OPKO Health 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Miraca Holdings 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Myriad Genetics 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Sonic Healthcare 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Primary Health Care 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Healthscope 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Foundation Medicine 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Acm Global Laboratories 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.ARUP Laboratories 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Fulgent Genetics 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.Invitae 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14.Mayo Medical Laboratories 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 16.15.Spectra Laboratories 16.15.1. Company Overview 16.15.2. Product Portfolio 16.15.3. SWOT Analysis 16.15.4. Financial Overview 16.15.5. Strategic Overview 16.16.American Medical Laboratories 16.16.1. Company Overview 16.16.2. Product Portfolio 16.16.3. SWOT Analysis 16.16.4. Financial Overview 16.16.5. Strategic Overview 16.17.Genomic Health 16.17.1. Company Overview 16.17.2. Product Portfolio 16.17.3. SWOT Analysis 16.17.4. Financial Overview 16.17.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics